Novo Nordisk AS ADR
NVO: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| p@ | LOCK|@D | LOCK|<N&m&!< |
Novo Nordisk Earnings: Strong Quarter, but Full-Year 2026 and 2027 Still Teetering at Edge of Growth
Novo reported 6% top-line growth and a 3% operating profit decline in the third quarter. Management raised full-year guidance to flat sales and operating profit at the midpoint at constant currencies (from a 3% decline at the midpoint). Shares closed 6% higher in Denmark on Nov. 4.
